GlassScriptPhysician profile
Frederick Purnell
NPI 1952704397
$3,226.76
in general payments reported to CMS, 2019-2025
29 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $383 · 2023: $1,076 · 2024: $1,533 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,844.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,843.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $402.80 | 2023-2025 | |
| Lilly USA, LLC | $362.99 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $344.94 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $289.25 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $263.40 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $248.15 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.11 | 2023-2024 | Jardiance |
| Astellas Pharma US INC | $142.62 | 2023-2024 | Veozah |
| Corium, LLC | $136.71 | 2022-2024 | Azstarys |
| Exact Sciences Corporation | $107.53 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $103.38 | 2022-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $94.14 | 2022-2024 | Rexulti |
| Amgen INC. | $86.57 | 2024 | Otezla, Repatha |
| Abbott Laboratories | $69.60 | 2024 | Freestyle Libre |
| Biohaven Pharmaceutical Holding Company LTD. | $55.70 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $54.34 | 2023-2024 | Dexcom G6 Transmitter |
| Dynavax Technologies Corporation | $32.62 | 2023-2024 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $31.05 | 2022-2023 | Quviviq |
| Antares Pharma, INC. | $30.05 | 2024-2025 | Xyosted |
| Janssen Pharmaceuticals, INC | $29.00 | 2022 | |
| Lundbeck LLC | $26.50 | 2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $22.07 | 2023 | |
| Upsher-Smith Laboratories LLC | $19.88 | 2023 | |
| Tris Pharma INC | $18.99 | 2023 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $18.52 | 2024 | Fanapt |
| Noven Therapeutics, LLC | $16.71 | 2023 | Xelstrym |
| Halozyme INC | $14.11 | 2023 | |
| Alexion Pharmaceuticals, INC. | $13.05 | 2022 | |
| Sanofi Pasteur INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Purnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.